Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN Study. by Michetti, P. et al.
ORIGINAL RESEARCH
Impact of Treatment-Related Beliefs on Medication
Adherence in Immune-Mediated Inflammatory
Diseases: Results of the Global ALIGN Study
Pierre Michetti . John Weinman . Ulrich Mrowietz . Josef Smolen .
Laurent Peyrin-Biroulet . Edouard Louis . Dieter Schremmer .
Namita Tundia . Pascal Nurwakagari . Nicole Selenko-Gebauer
Received: September 1, 2016 / Published online: November 16, 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: Medication adherence is critical
in chronic immune-mediated inflammatory
diseases (IMIDs) and could be affected by
patients’ treatment-related beliefs. The
objective of this study was to determine beliefs
about systemic medications in patients with
IMIDs and to explore the association of those
beliefs and other factors with adherence.
Methods: This was a multi-country,
cross-sectional, self-administered survey study.
Included were adults diagnosed with one of six
IMIDs receiving conventional systemic
medications and/or tumor necrosis factor
inhibitors (TNFi). Patients’ necessity
beliefs/concerns towards and adherence to
treatments were assessed by the Beliefs about
Medicines Questionnaire and four-item Morisky
Medication Adherence Scale. Correlation of
patients’ beliefs about treatment and other
factors with adherence were evaluated by
multivariable regression analyses.
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Results: Among studied patients (N = 7197),
32.0% received TNFi monotherapy, 27.7%
received TNFi–conventional combination
therapy, and 40.3% received conventional
medications. Across IMIDs, high adherence to
systemic treatment was more prevalent in TNFi
groups (61.3–80.7%) versus corresponding
conventional treatment groups (28.4–64.7%).
In at least four IMIDs, greater perception of the
illness continuing forever (P\0.001), of the
treatment helping (P\0.001), and more
concerns about the illness (P\0.01), but not
clinical parameters, were associated with higher
treatment necessity beliefs. Higher treatment
necessity beliefs, older age, Caucasian race, and
TNFi therapy were associated with high
medication adherence in at least four IMIDs.
Conclusions: Treatment necessity beliefs were
higher than concerns about current medication
in patients with IMID. Illness perceptions had a
greater impact on treatment necessity beliefs
than clinical parameters. Older age, greater
treatment necessity beliefs, and TNFi therapy
were associated with high self-reported
medication adherence in at least four IMIDs.
Trial registration: ACTRN12612000977875.
Funding: AbbVie.
Keywords: Crohn’s disease; Cross-sectional
study; Illness perception; Medication beliefs;
Rheumatoid arthritis; Ulcerative colitis
INTRODUCTION
Treatment adherence is of particular
importance in immune-mediated
inflammatory diseases (IMIDs), as these
chronic conditions require long-term
management. Non-adherence to treatment in
patients with IMIDs has been shown to
negatively impact patient outcomes, such as
increased disease activity or reduced treatment
efficacy [1–3], increased risk of clinical
recurrence (‘‘flares’’) [4–6], lower quality of life
[7], and risk of hospitalization or prolongation
of hospital stay [8–10], resulting in increased
healthcare resource use and costs [8–12].
According to the World Health
Organization, adherence to long-term therapy
is defined as the degree to which a person’s use
of medication, following a diet, and/or
adopting lifestyle changes is consistent with
agreed-upon recommendations from a
healthcare provider [13]. Many patients do
not, however, take their medication as
prescribed, or their adherence to therapy
fluctuates over time, engendering difficulties
in monitoring patient adherence by the treating
physician. Depending on the methodology of
adherence measurement and received
medication, studies reveal non-adherence to
prescribed therapies in a large proportion of
patients with IMIDs (reported adherence rates:
psoriasis [PS], 22–67% [14]; rheumatoid arthritis
[RA], 21–99% [1, 2, 15–21]; Crohn’s disease [CD]
or ulcerative colitis [UC], 28–96%
[4, 10, 15, 22, 23]). Currently, it is unclear
whether lack of adherence relates to particular
diseases and therapies or is, in principle, similar
across diseases and types of treatment. Different
diseases affect patients to a greater or lesser
extent, and differences in age, disease severity
and duration, and beliefs about medications
also may have an effect on adherence to
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therapy. The ALIGN study was designed to
address these questions.
Non-adherence to therapy appears to be
intentional in the majority of cases, as only
12% of patients with chronic diseases report
problems remembering to take their
medication (unintentional non-adherence)
[24]. Studies examining long-term
conditions have shown that intentional
non-adherence may result in part from
doubts about the real need for and expected
benefit from a certain medication, paired
with concerns about its potential side effects
and ability to improve long-term outcomes
[25–27]. These overall attitudes towards
medications are subjective, relate to
patients’ overall trust in their medicines,
and have been shown to differ, even in
groups of patients treated with the same
medication for the same condition [28].
The primary objective of the ALIGN study
was to assess necessity beliefs and risk concerns
in patients with any of six chronic IMIDs
towards their systemic medication. Secondary
objectives were to assess adherence to different
IMID treatments, to determine the factors
affecting patients’ beliefs about systemic
medications, and to explore the association
between patients’ beliefs about treatments and
other factors with medication adherence in
patients with IMIDs.
METHODS
ALIGN was a global, multi-country,
cross-sectional, self-administered survey
study conducted between June 2012 and
October 2013 that enrolled 7328 patients
from 501 sites in six geographic areas
(Fig. S1); data from 7197 patients were used
in this analysis.
Patients
Patients included in ALIGN were at least 18 years
old and attended routine outpatient visits. All
patients had either RA, ankylosing spondylitis
(AS), psoriatic arthritis (PsA), PS, CD, or UC
diagnosed by a rheumatologist (RA, PsA, and
AS), dermatologist (PsA and PS), or
gastroenterologist (CD and UC), respectively,
and were being treated with systemic
conventional disease-modifying antirheumatic
drugs (DMARDs), immunosuppressants,
glucocorticoids, nonsteroidal anti-inflammatory
drugs (NSAIDs; for patients with AS only), and/or
TNFi. Current and prior disease severity was rated
by the investigator on a five-point scale (mild,
mild to moderate, moderate, moderate to severe,
or severe). Treatment response was evaluated by
the investigator (complete response, partial
response, and not evaluable).
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent for participation was
obtained from all patients included in the
study. This study was approved by the local
ethics committee of each participating country.
Study Procedures
Consecutive patient recruitment was carried out
if patients agreed to participate in the study.
Data collection occurred at a single visit during
routine follow-up. Patients were asked to
complete four validated questionnaires: the
Beliefs about Medicines Questionnaire (BMQ)
[29], scoring treatment necessity beliefs and
concerns on a 5-point Likert scale (1 = strongly
disagree; 5 = strongly agree; Table S1a, b); the
four-item Morisky Medication Adherence Scale
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(MMAS-4) [30, 31], consisting of four questions
(yes = 0; no = 1), with high adherence defined
as a score of 4; the Brief Illness Perception
Questionnaire (BIPQ; Table S1c) [32], measuring
perception of illness with eight questions scored
using an 11-point scale [0–10]); and Patient
Health Questionnaire-2 (PHQ-2) [33], which
consists of two questions measuring depressive
symptoms, scored on a 4-point rating scale
(0 = not at all; 3 = nearly every day). Validated
translations were provided in the languages of
patients expected to enroll. The questionnaires
were completed on paper and placed in sealed
envelopes by the patient to guarantee
confidentiality. The investigators collected
information on patient demographics, social,
economic, and educational background,
IMID-related data, prior and current
treatment, and response to therapy.
Comorbidity was collected from the patient
files or by interviewing the patient and recorded
in the case report form by the investigator
during the documentation visit. Comorbidity
was then coded using the Medical Dictionary
for Regulatory Activities, version 16.1.
Statistical Analyses
Data analysis was conducted using information
from 7197 of 7328 enrolled patients who had
available data for at least one of the patient
questionnaires used in the study. Current
treatments were categorized as TNFi
monotherapy (‘‘TNFi mono’’), TNFi combined
with conventional therapies (‘‘TNFi combo’’), or
conventional therapies only (‘‘conventional
only’’). DMARDs, immunosuppressants,
glucocorticoids, and NSAIDs (only allowed in
patients with AS) were classified as conventional
therapy. BMQ-Specific Necessity and Concerns
subscales ratings and the proportion of highly
adherent patients (defined as MMAS-4 = 4) were
estimated in the TNFi monotherapy group, the
TNFi combo groups, and the conventional only
group. This definition of high adherence was
the same as for the original Morisky, Green, and
Levine adherence scale, in which a score of 4
had good predictive validity for adherence in
patients with high blood pressure [34]. BMQ
ratings and MMAS-4 adherence rates in the
TNFi combo group were evaluated separately for
the TNFi component (‘‘TNFi combo-TNFi
rating’’) and the conventional therapy
component (‘‘TNFi combo-conventional
rating’’), as beliefs and adherence patterns
might differ. No statistical comparisons of
differences between treatment groups were
performed.
Multivariable regression analyses were
employed to evaluate the factors affecting
BMQ-Specific Necessity/Concerns scores and
medication adherence. Covariates in these
analyses consisted of age, gender, disease
duration, current disease severity, prior disease
severity, treatment response (complete vs
non-complete), treatment duration, number of
pretreatments, BIPQ1–BIPQ8 subscores, PHQ-2
total score, number of concomitant diseases,
education (years), living arrangement (living
alone, living with partner, or living with
others), residence (urban vs rural), and
Caucasian ethnicity (Caucasian vs
non-Caucasian). All demographic and clinical
data were collected from the patient files or by
interviewing the patients. Regression analyses
were performed separately for all six
indications. A backward selection approach,
based on the predicted residual sum of square
(PRESS) criteria and removal when P[0.05, was
used in multivariable linear and logistic
regression analyses to determine predictors of
high BMQ-Specific scores and high medication
adherence. To account for the within-subject
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correlations, the final model was refitted by a
random effects linear model with a patient
indicator as a random intercept. To prevent
overfitting of the data, the model with the
smallest prediction error (minimal PRESS
estimate) was selected as the final model. All
statistical analyses were performed using SAS
9.2 (SAS Institute, Cary, NC, USA).
RESULTS
Disease and Patient Characteristics
Patient Demographics
ALIGN enrolled 7328 patients from 34
countries; data from 7197 patients enrolled in
33 countries who provided documentation for
at least one questionnaire were used in the
analysis. Patients were recruited from four
different regions (Fig. S1); 56.8% of the
patients were recruited in Western Europe and
Canada. The percentages of female patients in
the study varied depending on the IMID; mean
ages ranged from 38.0 years (CD) to 54.8 years
(RA; Table 1). Additional patient characteristics
are summarized in Table S2.
Disease Characteristics
The mean duration of disease varied across the
six IMIDs (Table 1). Prior to the start of current
IMID treatment, 68.8% of the patients had a
disease severity rated as moderate to severe or
severe, whereas under their current therapies,
only 12.2% had disease severity rated as
moderate to severe or severe (Table 1). A
statistically significant improvement in
patients’ disease severity, from before the start
of current treatment to the current state, was
reported by the investigators (P\0.0001;
Wilcoxon test), corresponding to an
improvement of disease severity in 80.3% of
patients, no change in 15.4%, and worsening in
4.3%.
A large proportion of patients were suffering
from comorbidity, with the highest proportion
in the RA population (66.9%; Table 1). Vascular,
metabolic and nutritional, and musculoskeletal
and connective tissue disorders were common
in patients receiving therapies for IMIDs;
hypertension was the most common
comorbidity across all IMIDs.
IMID Medications
Current IMID treatments were generally evenly
distributed between TNFi monotherapy, TNFi
combination therapy, and conventional
DMARDs in patients with PsA and CD,
whereas TNFi monotherapy was predominant
in patients with PS (56.9%) and AS (45.0%), and
conventional systemic treatments (DMARDs,
immunosuppressants, glucocorticoids, or [only
for patients with AS] NSAIDs) were
predominant in patients with RA (58.7%) and
UC (54.9%; Table 1). Additional treatment
details are in Table S2.
Beliefs Towards Medication
and Treatment Adherence
Specific Beliefs Towards Current IMID
Medications
BMQ-Specific Necessity subscale scores indicated
a relatively high perceived need for current
treatment (Fig. 1a; Table S3a). Numerically
higher mean scores were reported for patients
receiving TNFi (either as monotherapy or as a
combination therapy) compared with
conventional therapy alone. BMQ-Specific
Concerns subscale scores were lower than those
observed for the BMQ-Specific Necessity
subscale, and were in a similar range across
the three treatment groups (Fig. 1a, b;
Tables S3a, b).
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Beliefs About Medications in General
According to BMQ-General subscale results
covering general medication overuse and harm
beliefs (Table S1b), we found a significant
proportion of patients with negative beliefs
about medication in general (e.g., perception
of ‘‘all medicines to be poison’’ [9.0–20.3% of
patients] and of ‘‘most medicines to be
addictive’’ [14.6–24.0%]). These beliefs were
highest in patients with RA and were lowest in
patients with CD and UC (Table S4). Agreement
with the belief that ‘‘physicians place too much
trust on medicines’’ ranged from 28.4% to
45.6%, depending on the specific IMID. Up to
28.2% of patients believed that they ‘‘should
stop their treatment for a while every now and
Fig. 1 Mean with lower and upper 95% conﬁdence
interval values for BMQ-Speciﬁc subscales (a) Necessity
and (b) Concerns by IMID diagnosis and treatment group.
AS ankylosing spondylitis, BMQ Beliefs about Medicines
Questionnaire, CD Crohn’s disease, IMID
immune-mediated inﬂammatory disease, PsA psoriatic
arthritis, PS psoriasis, RA rheumatoid arthritis,
TNFi tumor necrosis factor inhibitor, UC ulcerative
colitis. Missing data for n = 28 (TNFi mono),
n = 37 (TNFi combo - TNFi rating), n = 81
(TNFi combo - Conventional rating), and n = 45
(Conventional only)
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then’’; patients with PS agreed with this
statement most frequently, and patients with
CD and UC had the lowest agreement rate.
Illness Perception and Depressive Symptoms
Patients understood the chronic nature of their
diseases, as reflected by high mean scores across
IMIDs (8.5–9.0) in response to the BIPQ
question ‘‘How long do you think your illness
will continue?’’ Patients gave high mean BIPQ
scores (8.3–8.5) for how much they thought
that their treatment could help their illness. The
lowest BIPQ scores were regarding how much
their illness affected their life, how much they
experienced symptoms, and how much their
illness affected them emotionally (Table S5).
The percentage of patients with signs and
symptoms suggestive of depression (PHQ-2 total
score C4) ranged from 13.7% (CD) to 20.5%
(RA; Table S6).
Self-Reported Adherence
Across all indications, patients reporting high
adherence to their current IMID treatment
(MMAS-4 = 4) were more prevalent in
TNFi-treated monotherapy and combination
therapy groups (61.3–80.7%) compared with
conventional treatment groups (28.4–64.7%;
Fig. 2). For patients on TNFi combination
therapy, the proportion of patients reporting
to be highly adherent was greater for the TNFi
component than for the conventional therapy
component (Fig. 2). The lowest rate of highly
adherent patients was observed in the AS
population receiving conventional medication,
either alone (28.4%) or in combination therapy
(33.1%; Fig. 2).
Fig. 2 Self-reported adherence in patients on TNFi
monotherapy, TNFi combination therapy, or conventional
therapy by MMAS-4. *Patients with high adherence were
deﬁned as those with an MMAS-4 score = 4. AS
ankylosing spondylitis, BMQ Beliefs about Medicines
Questionnaire, CD Crohn’s disease, IMID
immune-mediated inﬂammatory disease, MMAS-4
four-item Morisky Medication Adherence Scale,
PS psoriasis, PsA psoriatic arthritis, RA rheumatoid
arthritis, TNFi tumor necrosis factor inhibitor, UC
ulcerative colitis. TNFi mono valid data for n = 2277,
missing data for n = 24, TNFi combo - TNFi rating
valid data for n = 1940, missing data for n = 57, TNFi
combo - Conventional rating valid data for n = 1918,
missing data for n = 79, Conventional only valid data for
n = 2861, missing data for n = 38
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Multivariable Regression Analyses
Logistic Multivariable Regression Analyses:
MMAS-4 Adherence Scores
In all IMIDs except PsA, TNFi monotherapy or
combination therapy was associated with 2- to
21-fold higher likelihood of high medication
adherence compared with conventional only
therapy (Table 2; Fig. S2). A direct positive
association of older age and greater
BMQ-Specific Necessity score with high
medication adherence was observed in all six
IMIDs, while Caucasian race was associated
with greater medication adherence in four of
six IMIDs (Table 2; Fig. S2). Higher
BMQ-Specific Concerns scores were associated
with less medication adherence in RA, AS, and
PS. Factors associated with higher treatment
necessity beliefs and/or higher medication
adherence in at least four IMIDs are
summarized in Fig. 3.
Factors Affecting Necessity Beliefs
and Concerns Towards Current IMID
Medication
Higher BIPQ timeline scores (all IMIDs), BIPQ
treatment control scores (all IMIDs), and BIPQ
illness concerns (RA, AS, PsA, and PS) were
associated with greater BMQ-Specific Necessity
scores (Table S7). Higher scores on the BIPQ
Fig. 3 Summary of factors associated with higher
treatment necessity beliefs and/or medication adherence
in at least four of six IMIDs (results from multivariable
regression analyses). High adherence: MMAS-4 = 4;
: = higher/older; three ﬁlled diamonds positive association
identiﬁed in all of the six IMIDs; two ﬁlled diamonds
positive association identiﬁed in four to ﬁve of the six
IMIDs, but variable excluded from testing in at least one
indication; one ﬁlled diamond positive association
identiﬁed in four to ﬁve of the six IMIDs, but
non-signiﬁcant result in at least one indication; 1variable
excluded from testing in PsA; 2variable excluded from
testing in CD and UC; 3variable excluded from testing in
PsA, result non-signiﬁcant for CD; 4result non-signiﬁcant
for RA and PsA; 5variable excluded from testing in PsA
and CD; 6non-signiﬁcant result in PsA; #versus
conventional only therapy; §OR results for the impact of a
1-year or 1-unit increase presented; empty diamond as
determined by BMQ-Speciﬁc Necessity. BIPQ Brief Illness
Perception Questionnaire, BMQ Beliefs about Medicines
Questionnaire, CD Crohn’s disease, IMID immune-mediated
inﬂammatory disease, MMAS-4 four-item Morisky
Medication Adherence Scale, OR odds ratio, PHQ-2 Patient
Health Questionnaire-2, PsA psoriatic arthritis, RA
rheumatoid arthritis, TNFi tumor necrosis factor inhibitor,
UC ulcerative colitis
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illness concern and emotional impact of illness
scales (all IMIDs) were associated with higher
BMQ-Specific Concerns scores, while lower BIPQ
coherence score (all IMIDs) and lower BIPQ
treatment control scores (all IMIDs except AS)
were associated with lower treatment concerns
(Table S8). ‘‘Complete treatment response’’ and
treatment type were the only disease- or
treatment-related factors with a significant
impact on treatment necessity beliefs or
treatment concerns in four or more IMIDs.
TNFi in combination therapy (all IMIDs) and
TNFi monotherapy (AS, PS, CD, and UC) were
associated with greater BMQ-Specific Necessity
scores. Increased depressive symptoms were
associated with higher BMQ-Specific Concerns
and Necessity scores, and Caucasian race was
associated with lower treatment concerns.
DISCUSSION
Various ‘‘patient-supporting’’ approaches (e.g.,
telephone follow-up and supportive care) have
been established and tested in order to improve
medication adherence. Many studies on the
impact of patient support methods have been
small in size and produced mixed results
[35, 36]. To devise successful programs and to
provide targeted adherence support, it is crucial
to understand key drivers for enhanced
treatment adherence in patients with IMIDs.
To our knowledge, ALIGN is the first study to
analyze the association between patients’ beliefs
about their illness, as well as about their
systemic medications, and self-reported
adherence patterns in a large multi-country
population with more than 7000 patients
across six different IMIDs. Four validated
questionnaires were used in the ALIGN study,
allowing examination of the effects of various
factors on patients’ medication-related beliefs
and treatment adherence in a diverse set of
multivariable regression analyses. Identifying
the factors that have the most effect on
adherence to therapy can help develop models
to predict the risk of non-adherence for patients
with specific IMIDs. Targeted intervention can
then be designed to improve adherence to
therapy in patients at high risk of
non-adherence.
Several key findings from the ALIGN study
provide new insight into beliefs and concerns of
patients with IMIDs towards their systemic
medication. BMQ-Specific Concerns scores for
different treatment groups across indications
were in a similar range, suggesting that patients
today are not significantly more concerned
about potential side effects of TNFi than they
are about those associated with conventional
systemic treatments. However, the results for
BMQ-General revealed that a significant
proportion of patients still had negative beliefs
about medication in general (e.g., perception of
all medicines to be poison and of most
medicines to be addictive).
Multivariable regression analyses revealed
that, in all IMIDs except PsA, TNFi
monotherapy or in combination therapy was
associated with a 2- to 21-fold higher likelihood
of high medication adherence compared with
conventional only therapy. ‘‘Complete response
to current treatment’’ was identified as an
independent predictor of either high or low
adherence in patients with PsA or UC,
respectively. However, only few clinical
parameters were associated with higher
treatment necessity beliefs or higher
medication adherence, possibly because the
majority of patients displayed low disease
activity and had responded to their treatment
regimen. These results generally correspond
with published data from Dutch investigations
for RA, in which clinical parameters did not
significantly influence non-adherence [19, 20].
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In ALIGN, perceptions about the necessity of
the medication rather than concern beliefs
affected high medication adherence in a
majority of the IMIDs. These observations are
consistent with results from four [19, 20, 37, 38]
of the six [19, 20, 28, 37–39] previous studies
assessing associations between beliefs about
medication and non-adherence in patients with
RA. Our data suggest that necessity beliefs about
medication are a prerequisite for taking
medicines, and that necessity beliefs seem to
outweigh concerns about the medication. A
systemic review and meta-analysis across
various diseases supports this observation [25],
although, in our regression analysis, a
relationship between higher concerns and less
adherence was noted only in RA, AS, and PS.
Across all six IMIDs, patients with higher
medication necessity beliefs were those who
believed more strongly that their condition
would be longer lasting and was more
controllable by treatment, and who had greater
concerns about their illness. Direct associations
of the perception of the illness to continue
longer/forever (in RA) and the perception of the
treatment to help (in PS and CD) with higher
medication adherence, and of experiencing
more symptoms with lower adherence, were
seen with certain IMIDs but not all, indicating a
rather indirect association of several BIPQ items
with treatment adherence via their effect on
treatment necessity beliefs in the majority of
IMIDs. In addition, in at least four of the six
IMIDs, older age and Caucasian race were
associated with better medication adherence.
Age or race/ethnicity as factors affecting
medication adherence were noted in patients
with RA or other immune diseases in previous
studies [18, 39–44]. In our study, Caucasians in
general harbored significantly less concerns and
overuse beliefs but not higher treatment
necessity beliefs comparedwithnon-Caucasians.
One limitation of the ALIGN study was that
illness perception, beliefs about medication, risk
of depression, and adherence results were based
on self-reported outcomes that may be
influenced by self-presentational and recall
biases. Patients may overestimate the extent of
their adherence in an attempt to ‘‘please the
doctor,’’ or if they believe that admitting to
non-adherencemay result in adverse judgments.
However, in our study patients’ responses were
confidential; thus, the risk of overestimating
adherence to ‘‘please the doctor’’ was reduced.
Another caveat is that the patients’ responses to
the specific questions in the questionnaires used
in this studymaynot capture all the complexities
of patients’ feelings. Additionally, for feasibility
reasons, no validated clinical scores were used to
assess disease severity or response to therapy, and
no uniform definitions or confirmations were
used for diagnosing the IMIDs. Furthermore,
confounding factors (e.g., disease severity,
treatment response, and number of
co-morbidities) may not be equally distributed
between the groups being compared in this
non-randomized study, which could lead to
bias and subsequent misinterpretation.
However, in our multivariable regression
analyses, we controlled for various confounding
factors so that such effects would be minimized
and false interpretation could be avoided.
Although different adherence measures were
applied in other studies, limiting comparability
with results from ALIGN, the percentages of
patients with PS or CD treated with TNFi
monotherapy and combination therapy who
reported high adherence based on the MMAS-4
corresponded to the adherence levels for
biologics reported in the same IMIDs by other
authors [8, 45]. Another limitation is the
cross-sectional rather than prospective design
of this study.However, thedataobtainedallowed
the formulation of a new hypothesis which can
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be tested prospectively in future studies.
Additionally, the proportion of patients
receiving TNFi therapy versus conventional
therapy in this study may not be representative
of typical practice. Finally, information about
thepercentageof screenedpatients that agreed to
participate in this study was not collected.
Despite its limitations, the large, global,
multicenter ALIGN study provides valuable
insight into factors affecting treatment-related
beliefs and medication adherence in patients
with IMIDs.
CONCLUSION
ALIGN is the first large cross-sectional study to
provide extensive data on the impact of various
factors, including patients’ beliefs about
medication, on medication adherence in
patients diagnosed with one of the six different
IMIDs. Treatment necessity beliefs are higher
than concerns about currentmedication in IMID
patients with well-controlled disease. Illness
perceptions appear to have a greater impact on
necessity beliefs about medication than clinical
parameters. Older age, greater treatment
necessity beliefs, and TNFi therapy are
associated with high self-reported medication
adherence across all IMIDs. Insights from the
ALIGNstudymayhelpdevelop tools to screen for
IMID patients at risk of poor adherence.
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